Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Paclitaxel in Upper GI Adenocarcinoma
NCT00020761Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2000
- Primary completion
- Dec 2002
- Modality
- Nanoparticles, Monoclonal Antibodies, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and Paclitaxel Micelles for Injection in esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (2 cohorts), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Antitumor activity at 5 months. Started Apr 2000; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabPaclitaxel Micelles for Injection
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00020761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020761.